Marshall Wace LLP Boosts Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Marshall Wace LLP raised its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 75.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,182 shares of the company's stock after purchasing an additional 15,545 shares during the period. Marshall Wace LLP owned 0.14% of Eton Pharmaceuticals worth $482,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ETON. Jump Financial LLC purchased a new position in shares of Eton Pharmaceuticals during the 4th quarter worth approximately $329,000. XTX Topco Ltd boosted its position in shares of Eton Pharmaceuticals by 29.6% during the fourth quarter. XTX Topco Ltd now owns 14,655 shares of the company's stock valued at $195,000 after purchasing an additional 3,351 shares in the last quarter. Barclays PLC purchased a new stake in Eton Pharmaceuticals in the fourth quarter worth $731,000. Raymond James Financial Inc. bought a new position in Eton Pharmaceuticals in the fourth quarter worth $147,000. Finally, Renaissance Technologies LLC raised its holdings in Eton Pharmaceuticals by 131.5% in the fourth quarter. Renaissance Technologies LLC now owns 193,100 shares of the company's stock worth $2,572,000 after purchasing an additional 109,700 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company's stock.

Eton Pharmaceuticals Stock Performance

Shares of ETON stock traded down $0.01 during mid-day trading on Thursday, hitting $17.22. The company's stock had a trading volume of 22,428 shares, compared to its average volume of 181,890. Eton Pharmaceuticals, Inc. has a 52-week low of $3.18 and a 52-week high of $18.41. The stock has a market cap of $461.81 million, a price-to-earnings ratio of -78.27 and a beta of 1.22. The business has a 50-day moving average price of $14.37 and a 200 day moving average price of $13.43.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The business had revenue of $11.65 million for the quarter, compared to analysts' expectations of $10.53 million. Equities research analysts predict that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. HC Wainwright reissued a "buy" rating and issued a $33.00 target price on shares of Eton Pharmaceuticals in a research note on Wednesday, March 19th. Craig Hallum raised their price objective on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, March 19th. Finally, B. Riley reiterated a "buy" rating and issued a $24.00 target price (up previously from $21.00) on shares of Eton Pharmaceuticals in a research note on Wednesday, March 19th.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.